Evidence map›Paper›PMID 34360616›Full record

ReviewInternational journal of molecular sciences2021

Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives.

Silvia Fernández-Francos, Noemi Eiro, Natalia González-Galiano, Francisco J Vizoso

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Nonantibiotic Treatment of Clinical Multidrug-Resistant Bacterial Isolates Using Chitosan Nanoparticles as a Carrier for the Supernatant of Mesenchymal Stem Cells.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Article
  5. Review
  6. Article
  7. Advancements in lung regeneration: from bench to bedside.Journal of translational medicine · 2025
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Combined Light and Thermal Stimulation of Bone Marrow Stem Cells.Journal of lasers in medical sciences · 2024
    Article
  20. Multipotent mesenchymal stromal/stem cell-based therapies for acute respiratory distress syndrome: current progress, challenges, and future frontiers.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Silvia Fernández-FrancosResearch Unit, Fundación Hospital de Jove, Av. Eduardo Castro, 161, 33290 Gijón, Spain.ORCID 0000-0003-1937-6078
Noemi EiroResearch Unit, Fundación Hospital de Jove, Av. Eduardo Castro, 161, 33290 Gijón, Spain.
Natalia González-GalianoDepartment of Internal Medicine, Fundación Hospital de Jove, Av. Eduardo Castro, 161, 33290 Gijón, Spain.
Francisco J VizosoResearch Unit, Fundación Hospital de Jove, Av. Eduardo Castro, 161, 33290 Gijón, Spain.ORCID 0000-0002-2827-5511
Fundación Hospital de Jove · ES

Funding

Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, "Investing in your future" PI20/01122
6 · The paper itself

Abstract

Acute respiratory distress syndrome (ARDS) represents a current challenge for medicine due to its incidence, morbidity and mortality and, also, the absence of an optimal treatment. The COVID-19 outbreak only increased the urgent demand for an affordable, safe and effective treatment for this process. Early clinical trials suggest the therapeutic usefulness of mesenchymal stem cells (MSCs) in acute lung injury (ALI) and ARDS. MSC-based therapies show antimicrobial, anti-inflammatory, regenerative, angiogenic, antifibrotic, anti-oxidative stress and anti-apoptotic actions, which can thwart the physiopathological mechanisms engaged in ARDS. In addition, MSC secretome and their derived products, especially exosomes, may reproduce the therapeutic effects of MSC in lung injury. This last strategy of treatment could avoid several safety issues potentially associated with the transplantation of living and proliferative cell populations and may be formulated in different forms. However, the following diverse limitations must be addressed: (i) selection of the optimal MSC, bearing in mind both the heterogeneity among donors and across different histological origins, (ii) massive obtention of these biological products through genetic manipulations of the most appropriate MSC, (iii) bioreactors that allow their growth in 3D, (iv) ideal culture conditions and (v) adequate functional testing of these obtaining biological products before their clinical application.

Indexed as

Acute Lung InjuryCOVID-19ExosomesHumansMesenchymal Stem CellsMesenchymal Stem Cell TransplantationRespiratory Distress Syndromeacute lung injuryacute respiratory distress syndromeconditioned mediumCOVID-19exosomesmesenchymal stem cellspneumonia

Identifiers

PMID34360616
PMCPMC8346146
OpenAlexW3184805478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.